Quality Care Properties, Inc. Files Form 10-K Print E-mail
By PR Newswire:   
Thursday, 08 March 2018 17:54
Quality Care Properties, Inc. Files Form 10-K

BETHESDA, Md., March 8, 2018 /PRNewswire/ -- Quality Care Properties, Inc. (NYSE: QCP) (the "Company") today has filed with the

Securities and Exchange Commission its Annual Report on Form 10-K for the year ended December 31, 2017 (the "Form 10-K").  The Form 10-K is available on the Company's website at www.qcpcorp.com.

About QCP

Quality Care Properties, Inc. is one of the nation's largest actively managed real estate companies focused on post-acute/skilled nursing and memory care/assisted living properties. QCP's properties are located in 29 states and include 257 post-acute/skilled nursing properties, 61 memory care/assisted living properties, a surgical hospital and a medical office building.  For more information regarding QCP, visit www.qcpcorp.com.

For further information: C. Marc Richards, Chief Financial Officer, Quality Care Properties, Inc., (240) 223-4680

 

View original content with multimedia:http://www.prnewswire.com/news-releases/quality-care-properties-inc-files-form-10-k-300611272.html

SOURCE Quality Care Properties, Inc.

Related Links

http://www.qcpcorp.com


Read more https://www.prnewswire.com/news-releases/quality-care-properties-inc-files-form-10-k-300611272.html




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and
investor relation services from various entities and

Error. Page cannot be displayed. Please contact your service provider for more details. (25)

firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter

BioMedReports #Arbutus’ LNP Licensee #Alnylam Announces #FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloid… https://t.co/SuVNz1uM3i
BioMedReports Why CTI BioPharma Corp. Crashed Today https://t.co/hIobDGpboQ https://t.co/hIobDGpboQ
BMR:1